AR090699A1 - Compuestos inhibidores de la actividad de la arn polimerasa viral - Google Patents
Compuestos inhibidores de la actividad de la arn polimerasa viralInfo
- Publication number
- AR090699A1 AR090699A1 ARP130101229A ARP130101229A AR090699A1 AR 090699 A1 AR090699 A1 AR 090699A1 AR P130101229 A ARP130101229 A AR P130101229A AR P130101229 A ARP130101229 A AR P130101229A AR 090699 A1 AR090699 A1 AR 090699A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently
- formula
- group
- alkyl
- phosphoryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
- -1 aminothionyl Chemical group 0.000 abstract 4
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Genetics & Genomics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261625994P | 2012-04-18 | 2012-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090699A1 true AR090699A1 (es) | 2014-12-03 |
Family
ID=49384030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101229A AR090699A1 (es) | 2012-04-18 | 2013-04-16 | Compuestos inhibidores de la actividad de la arn polimerasa viral |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9580428B2 (OSRAM) |
| EP (1) | EP2838535B1 (OSRAM) |
| JP (2) | JP2015514772A (OSRAM) |
| KR (3) | KR102156819B1 (OSRAM) |
| CN (1) | CN104379146B (OSRAM) |
| AR (1) | AR090699A1 (OSRAM) |
| AU (1) | AU2013249344B2 (OSRAM) |
| BR (1) | BR112014025909B1 (OSRAM) |
| CA (1) | CA2870722C (OSRAM) |
| IL (1) | IL235123A (OSRAM) |
| MX (1) | MX363270B (OSRAM) |
| RU (1) | RU2654482C2 (OSRAM) |
| TW (1) | TWI664180B (OSRAM) |
| WO (1) | WO2013158746A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX348759B (es) | 2010-10-15 | 2017-06-28 | Biocryst Pharm Inc | Metodos y composiciones para inhibicion de polimerasa. |
| WO2014078778A2 (en) * | 2012-11-16 | 2014-05-22 | Biocryst Pharmaceuticals, Inc. | Antiviral azasugar-containing nucleosides |
| CN103864791B (zh) * | 2014-03-18 | 2016-01-27 | 福建天泉药业股份有限公司 | 一种恩替卡韦衍生物及其制备方法 |
| CN104513249B (zh) * | 2014-12-26 | 2016-08-31 | 苏州明锐医药科技有限公司 | 抗埃博拉病毒药物bcx4430的制备方法 |
| CA2973152A1 (en) * | 2015-01-07 | 2016-07-14 | Euro-Celtique S.A. | Process for manufacture of forodesine |
| TWI874791B (zh) * | 2020-02-18 | 2025-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| WO2021207386A1 (en) * | 2020-04-07 | 2021-10-14 | Biocryst Pharmaceuticals, Inc. | Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections |
| US20230285434A1 (en) * | 2020-04-14 | 2023-09-14 | Oyagen, Inc. | Method for treating arenaviridae infections |
| CN111704619B (zh) * | 2020-07-30 | 2021-10-19 | 四川大学 | 一种Forodesine的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| CA3098164A1 (en) * | 2020-11-05 | 2022-05-05 | Eurofins Cdmo Alphora Inc. | Process for preparation of advanced intermediate for eribulin synthesys |
| WO2023022216A1 (ja) | 2021-08-20 | 2023-02-23 | 塩野義製薬株式会社 | ウイルス増殖抑制作用を有するヌクレオシド誘導体及びそれらのプロドラッグ |
| CN113666941B (zh) * | 2021-09-01 | 2023-03-10 | 浙江珲达生物科技有限公司 | 一种2,3-O-异亚丙基-D-核糖酸-γ-内酯的重结晶方法 |
| US12552827B2 (en) | 2022-01-21 | 2026-02-17 | Biocryst Pharmaceuticals, Inc. | Synthesis of an antiviral azasugar triphosphate |
| CN116693541A (zh) * | 2023-06-15 | 2023-09-05 | 安徽大学 | 一种4-氯-5h-吡咯并[3,2-d]嘧啶的合成方法 |
| CN118359621B (zh) * | 2024-04-16 | 2025-05-16 | 上海陶术生物科技股份有限公司 | 加利司伟及加利司伟中间体的制备方法和相应的加利司伟中间体 |
| CN118359623B (zh) * | 2024-04-16 | 2025-06-27 | 上海陶术生物科技股份有限公司 | 一种呋咯地辛的合成方法、中间体及应用 |
| CN118359622B (zh) * | 2024-04-16 | 2025-08-26 | 上海陶术生物科技股份有限公司 | 加利司伟中间体的制备方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5985848A (en) * | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
| CA2696826C (en) * | 1999-04-08 | 2013-01-08 | Industrial Research Limited | Process for preparing inhibitors of nucleoside metabolism |
| MY141594A (en) * | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
| AU2001284564A1 (en) * | 2000-08-29 | 2002-03-13 | Albert Einstein College Of Medicine Of Yeshiva University | Nucleoside metabolism inhibitors |
| WO2002069903A2 (en) | 2001-03-06 | 2002-09-12 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| US7388002B2 (en) | 2001-11-14 | 2008-06-17 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| US7098334B2 (en) * | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| US20040242599A1 (en) | 2003-02-27 | 2004-12-02 | Biocryst Pharmaceuticals, Inc. | Cyclopentene nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| US20050187170A1 (en) | 2003-06-16 | 2005-08-25 | Biocryst Pharmaceuticals, Inc. | Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors |
| US20050080053A1 (en) | 2003-08-29 | 2005-04-14 | Biocryst Pharmaceuticals, Inc. | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| ATE465742T1 (de) * | 2003-09-05 | 2010-05-15 | Anadys Pharmaceuticals Inc | Tlr7-liganden zur behandlung von hepatitis c |
| US20070167353A1 (en) * | 2003-10-24 | 2007-07-19 | John Hilfinger | Prodrug composition |
| WO2006002231A1 (en) * | 2004-06-22 | 2006-01-05 | Biocryst Pharmaceuticals, Inc. | Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| US8133870B2 (en) | 2004-10-29 | 2012-03-13 | Biocryst Pharmaceuticals, Inc. | Therapeutic furopyrimidines and thienopyrimidines |
| BRPI0607770A2 (pt) * | 2005-02-28 | 2009-06-13 | Genelabs Tech Inc | compostos de nucleosideo tricìclico para tratamento de infecções virais |
| EP2537520A1 (en) * | 2005-03-29 | 2012-12-26 | Biocryst Pharmaceuticals, Inc. | Hepatics C therapies |
| US7632821B2 (en) * | 2005-08-09 | 2009-12-15 | Merck & Co., Inc. | Ribonucleoside cyclic acetal derivatives for the treatment of RNA-dependent RNA viral infection |
| WO2007069924A1 (en) * | 2005-12-15 | 2007-06-21 | Industrial Research Limited | Deazapurine analogs of 4'-aza-l-nucleosides |
| US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EA016830B1 (ru) | 2006-09-11 | 2012-07-30 | Саузерн Рисерч Инститьют | Азольные нуклеозиды и их применение в качестве ингибиторов вариальных рнк- и днк-полимераз |
| SI2114980T1 (sl) | 2007-01-12 | 2012-11-30 | Biocryst Pharm Inc | Protivirusni nukleozidni analogi |
| TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
| PL2411394T3 (pl) * | 2009-03-24 | 2015-01-30 | Biocryst Pharm Inc | Użyteczne sole farmaceutyczne 7-[(3r, 4r)-3-hydroksy-4-hydroksymetylopirolidyn-1-ylometylo]-3,5-dihydropirolo[3,2-d]pirymidyno-4-nu |
| MX348759B (es) | 2010-10-15 | 2017-06-28 | Biocryst Pharm Inc | Metodos y composiciones para inhibicion de polimerasa. |
-
2013
- 2013-04-16 AR ARP130101229A patent/AR090699A1/es active IP Right Grant
- 2013-04-17 RU RU2014145857A patent/RU2654482C2/ru active
- 2013-04-17 KR KR1020147032192A patent/KR102156819B1/ko active Active
- 2013-04-17 WO PCT/US2013/036945 patent/WO2013158746A1/en not_active Ceased
- 2013-04-17 BR BR112014025909-7A patent/BR112014025909B1/pt active IP Right Grant
- 2013-04-17 MX MX2014012525A patent/MX363270B/es unknown
- 2013-04-17 AU AU2013249344A patent/AU2013249344B2/en active Active
- 2013-04-17 CA CA2870722A patent/CA2870722C/en active Active
- 2013-04-17 CN CN201380031507.7A patent/CN104379146B/zh active Active
- 2013-04-17 US US14/395,355 patent/US9580428B2/en active Active
- 2013-04-17 KR KR1020217002466A patent/KR102409853B1/ko active Active
- 2013-04-17 KR KR1020207016520A patent/KR20200070428A/ko not_active Ceased
- 2013-04-17 EP EP13778292.6A patent/EP2838535B1/en active Active
- 2013-04-17 JP JP2015507145A patent/JP2015514772A/ja active Pending
- 2013-04-17 TW TW102113674A patent/TWI664180B/zh active
-
2014
- 2014-10-19 IL IL235123A patent/IL235123A/en active IP Right Grant
-
2017
- 2017-01-20 US US15/411,297 patent/US20170128454A1/en not_active Abandoned
-
2018
- 2018-01-19 JP JP2018007131A patent/JP6559266B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013249344A1 (en) | 2014-11-27 |
| KR102156819B1 (ko) | 2020-09-16 |
| MX363270B (es) | 2019-03-19 |
| EP2838535A1 (en) | 2015-02-25 |
| IL235123A (en) | 2017-09-28 |
| MX2014012525A (es) | 2015-01-15 |
| RU2014145857A (ru) | 2016-06-10 |
| CA2870722C (en) | 2020-05-12 |
| TW201345912A (zh) | 2013-11-16 |
| HK1206627A1 (en) | 2016-01-15 |
| CA2870722A1 (en) | 2013-10-24 |
| JP2018111692A (ja) | 2018-07-19 |
| EP2838535B1 (en) | 2019-03-06 |
| BR112014025909B1 (pt) | 2021-09-14 |
| US9580428B2 (en) | 2017-02-28 |
| KR20200070428A (ko) | 2020-06-17 |
| AU2013249344B2 (en) | 2018-06-07 |
| KR20150002844A (ko) | 2015-01-07 |
| US20170128454A1 (en) | 2017-05-11 |
| RU2654482C2 (ru) | 2018-05-21 |
| EP2838535A4 (en) | 2015-09-09 |
| KR20210011517A (ko) | 2021-02-01 |
| KR102409853B1 (ko) | 2022-06-15 |
| JP2015514772A (ja) | 2015-05-21 |
| BR112014025909A2 (OSRAM) | 2017-06-20 |
| US20150191472A1 (en) | 2015-07-09 |
| CN104379146B (zh) | 2018-07-10 |
| TWI664180B (zh) | 2019-07-01 |
| CN104379146A (zh) | 2015-02-25 |
| JP6559266B2 (ja) | 2019-08-14 |
| WO2013158746A1 (en) | 2013-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20180117A1 (es) | Inhibidores de indolamina-2,3-dioxigenasa para el tratamiento de cancer | |
| AR083069A1 (es) | Analogos de nucleotidos sustituidos | |
| BR112015018509A2 (pt) | compostos de imidazo piridina | |
| MX362060B (es) | Compuestos antivirales inhibidores del virus de hepatitis c (vhc) ns5b. | |
| EA201692010A1 (ru) | Фармацевтическое соединение | |
| MD20150052A2 (ro) | Lactame aril şi heteroaril condensate | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR088441A1 (es) | Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales | |
| WO2016077464A8 (en) | Amino acid derivatives and their uses | |
| PE20170206A1 (es) | Inhibidores espirociclicos sustituidos de la autotaxina | |
| NZ627250A (en) | Novel nicotinamide derivative or salt thereof | |
| MX377552B (es) | Proceso para preparar un compuesto antiviral de formula i. | |
| CO7160119A2 (es) | Derivados de imidazo[1,2-b]piridazina como inhibidor de cinasa | |
| JP2016530314A5 (OSRAM) | ||
| EA201400136A1 (ru) | Пестицидные способы применения замещенных 3-пиридилтиазольных соединений и производных для борьбы с животными-вредителями i | |
| AR091858A1 (es) | INHIBIDORES DE CISTATIONIN-g-LIASA (CSE) | |
| JP2016523906A5 (OSRAM) | ||
| BR112015014457A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c | |
| BR112015003380A2 (pt) | composto de pirazolopirimidina | |
| EA201290632A1 (ru) | Производные бетулина | |
| EA201301137A1 (ru) | N-замещенные гетеробициклические соединения и производные для борьбы с животными вредителями | |
| EA201170223A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРИДИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И НОВОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ МЕТ | |
| EA201692048A1 (ru) | Дигидротиазин и дигидрооксазин производные, обладающие ингибирующей bace1 активностью | |
| MY194307A (en) | Pyridone derivative having tetrahydropyranylmethyl group | |
| IN2014DN07082A (OSRAM) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |